Insider Trading March 4, 2026

Artivion SVP Sells $83,008 in Stock to Cover RSU Taxes; Company Posts Strong Q4 2025 Results

Jean Holloway's non-discretionary sale coincides with upbeat quarterly metrics and mixed analyst signals

By Hana Yamamoto AORT
Artivion SVP Sells $83,008 in Stock to Cover RSU Taxes; Company Posts Strong Q4 2025 Results
AORT

Jean F Holloway, senior vice president and general counsel at Artivion Inc. (NASDAQ: AORT), disposed of 2,183 shares on March 2, 2026, in a transaction disclosed on a Form 4. The sale - executed to satisfy tax withholding tied to restricted stock unit vesting - totaled $83,008 at an average price of $38.0249. The disclosure arrives as Artivion's share price sits at $38.62, up roughly 54% over the prior year, and on the heels of a fourth-quarter 2025 report that beat EPS expectations and delivered adjusted revenue gains.

Key Points

  • Jean F Holloway sold 2,183 shares on March 2, 2026, to cover tax withholding from RSU vesting; sale was non-discretionary.
  • Shares were sold at $38.0249 each, totaling $83,008; Holloway now directly owns 170,105 shares.
  • Artivion posted Q4 2025 EPS of $0.17 versus a $0.06 forecast and adjusted revenues of $118.3 million, beating certain analyst estimates while facing mixed revenue signal language.

Transaction details

Jean F Holloway, serving as senior vice president and general counsel at Artivion Inc. (NASDAQ: AORT), sold 2,183 shares of common stock on March 2, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were disposed of at a price of $38.0249 per share, producing gross proceeds of $83,008. The filing specifies that the sale was executed to satisfy tax withholding obligations associated with the vesting of restricted stock units and was not a discretionary transaction.

Post-transaction ownership and market context

After the sale, Holloway is reported to directly hold 170,105 shares of Artivion. At the time surrounding the disclosed transaction, AORT shares were trading at $38.62, a price level that represents an approximate 54% increase over the preceding 12 months.

Valuation and company metrics

Investment research referenced in the filing indicates that, per InvestingPro analysis, Artivion appears overvalued relative to Fair Value estimates. The company is noted to be profitable and carries a market capitalization of $1.85 billion. The filing also points readers toward further proprietary analysis and additional ProTips available in a dedicated Pro Research Report for subscribers seeking deeper context.

Recent operating results

Artivion reported fourth-quarter results for 2025 that outpaced earnings expectations, recording earnings per share of $0.17 versus a forecast of $0.06. On the top line, adjusted fourth-quarter revenues amounted to $118.3 million, described as an 18.5% year-over-year increase on a constant currency basis and excluding a one-time $2.3 million payment to the Italian government. That adjusted revenue figure topped Canaccord Genuity’s estimate of $115.6 million and the consensus expectation of $116.5 million.

Despite slightly missing revenue forecasts, the company's performance was characterized by strength in key product areas and progress on strategic growth initiatives.

Analyst action

Canaccord Genuity retained a Buy rating on Artivion but reduced its price target to $48.00 from $51.00, citing compressed multiples among comparable groups in the wake of a recent market sell-off. The firm’s maintained rating alongside a lower target reflects both endorsement of the business momentum and caution tied to broader valuation pressures.


For investors and market participants, the Form 4 filing provides a clear administrative rationale for the insider sale while the company’s quarterly results and the analyst reaction together outline current opportunities and valuation tensions facing Artivion.

Risks

  • Valuation risk - InvestingPro analysis indicates the stock appears overvalued relative to Fair Value estimates, which may affect investor sentiment and equity valuation - impacts equity markets and financial services sector.
  • Market multiple compression - Canaccord cited compressed multiples in comparable groups following a market sell-off, leading to a lowered price target despite a Buy rating - impacts equity analysts and institutional investor outlooks.
  • Revenue reporting nuance - Adjusted revenue beat estimates but language noting a slight miss introduces uncertainty about top-line consistency and comparability - impacts company-specific operational assessment and medical-device/healthcare suppliers if applicable.

More from Insider Trading

Major Holder of AleAnna Disposes $535k in Stock as Shares Rally; Company Secures 20-Year Gas Concession Mar 4, 2026 Shift4 Investor Isaacman Buys $2.0M of Class A Stock Amid Analyst Caution Mar 4, 2026 ACI Worldwide Director Adds 3,000 Shares in March Purchase Mar 4, 2026 ACI Worldwide Director Acquires $100,550 in Stock as Company Posts Strong Q4 Results Mar 4, 2026 Skyward Specialty CFO Makes Small Stock Purchase as Company Posts Strong Q4 Results Mar 4, 2026